Picture3.jpg
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
09. Juni 2023 09:30 ET | Clearmind Medicine Inc.
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv, Israel / Vancouver, Canada, June 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:...
Picture3.jpg
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
12. Mai 2023 09:00 ET | Clearmind Medicine Inc.
IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Picture3.jpg
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
27. April 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Picture3.jpg
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
21. April 2023 08:30 ET | Clearmind Medicine Inc.
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) --...
Picture3.jpg
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
20. April 2023 05:37 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on...
Picture3.jpg
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
14. Februar 2023 08:30 ET | Clearmind Medicine Inc.
Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm Tel Aviv, Israel /...
Picture3.jpg
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
10. Januar 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...